<SEC-DOCUMENT>0001493152-23-034859.txt : 20230929
<SEC-HEADER>0001493152-23-034859.hdr.sgml : 20230929
<ACCEPTANCE-DATETIME>20230929163030
ACCESSION NUMBER:		0001493152-23-034859
CONFORMED SUBMISSION TYPE:	424B3
PUBLIC DOCUMENT COUNT:		3
FILED AS OF DATE:		20230929
DATE AS OF CHANGE:		20230929

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Qualigen Therapeutics, Inc.
		CENTRAL INDEX KEY:			0001460702
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				263474527
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		424B3
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-269088
		FILM NUMBER:		231296163

	BUSINESS ADDRESS:	
		STREET 1:		2042 CORTE DEL NOGAL
		STREET 2:		CARLSBAD
		CITY:			CALIFORNIA
		STATE:			CA
		ZIP:			92011
		BUSINESS PHONE:		(760) 918-9165

	MAIL ADDRESS:	
		STREET 1:		2042 CORTE DEL NOGAL
		STREET 2:		CARLSBAD
		CITY:			CALIFORNIA
		STATE:			CA
		ZIP:			92011

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	RITTER PHARMACEUTICALS INC
		DATE OF NAME CHANGE:	20090402
</SEC-HEADER>
<DOCUMENT>
<TYPE>424B3
<SEQUENCE>1
<FILENAME>form424b3.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">&nbsp;<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right">Filed
                                            Pursuant to Rule 424(b)(3)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right">Registration Statement No. 333-269088</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">PROSPECTUS</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 18pt"><B>3,958,537
Shares</B></FONT></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><IMG SRC="form424b3_001.jpg" ALT=""></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 14pt"><B>Common
Stock</B></FONT></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
prospectus relates to the resale or other disposition from time to time by the selling stockholder named herein of up to an aggregate
of 3,958,537 shares of our common stock, par value $0.001 per share (the &ldquo;Resale Shares&rdquo;), which may be issued to the selling
stockholder pursuant to the terms of an 8% Senior Convertible Debenture in the aggregate principal amount of $3,300,000 issued to the
selling stockholder on December 22, 2022 (the &ldquo;Debenture&rdquo;) and the warrant (the &ldquo;Warrant&rdquo;) issued to such selling
stockholder in connection with the issuance of the Debenture.</FONT></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
selling stockholder may offer and sell or otherwise dispose of the Resale Shares described in this prospectus from time to time through
public or private transactions at prevailing market prices, at prices related to prevailing market prices or at privately negotiated
prices. The selling stockholder will bear all underwriting fees, commissions and discounts, if any, attributable to the sales of Resale
Shares and any transfer taxes. We will bear all other costs, expenses and fees in connection with the registration of the Resale Shares.
See &ldquo;Plan of Distribution&rdquo; for more information on how the selling stockholder may sell or dispose of its Resale Shares.</FONT></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
will not receive any proceeds from the sale of the Resale Shares by the selling stockholder.</FONT></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
common stock is listed on The Nasdaq Capital Market under the trading symbol &ldquo;QLGN.&rdquo; On August 31, 2023, the closing
price of our common stock was $1.04 per share.</FONT></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Investing
in shares of our common stock involves a high degree of risk. You should review carefully the risks and uncertainties described in the
section titled &ldquo;Risk Factors&rdquo; on page 5 of this prospectus and any similar section contained in the applicable prospectus
supplement and in any free writing prospectuses we have authorized for use in connection with a specific offering, and under similar
headings in the documents that are incorporated by reference into this prospectus.</B></FONT></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Neither
the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or determined
if this prospectus is truthful or complete. Any representation to the contrary is a criminal offense.</B></FONT></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>The
date of this prospectus is September 7, 2023.</B></FONT></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>TABLE
OF CONTENTS</B></FONT></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 0.1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Page</B></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#qg_001">ABOUT THIS PROSPECTUS</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">i</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#qg_002">SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ii</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#qg_003">PROSPECTUS SUMMARY</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#qg_004">THE OFFERING</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#qg_005">RISK FACTORS</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#qg_006">USE OF PROCEEDS</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#qg_007">SELLING STOCKHOLDER</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#qg_008">PLAN OF DISTRIBUTION</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">9</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#qg_009">DESCRIPTION OF OUR CAPITAL STOCK</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">11</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#qg_010">LEGAL MATTERS</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">14</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#qg_011">EXPERTS</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">14</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#qg_012">WHERE YOU CAN FIND ADDITIONAL INFORMATION</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">14</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#qg_013">INCORPORATION OF CERTAIN INFORMATION BY REFERENCE</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">15</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="qg_001"></A>ABOUT
THIS PROSPECTUS</B></FONT></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
prospectus is part of a registration statement on Form S-1 that we filed with the Securities and Exchange Commission (the &ldquo;SEC&rdquo;).
The selling stockholder referred to in this prospectus may from time to time sell the shares of common stock described in this prospectus
in one or more offerings or otherwise as described under &ldquo;Plan of Distribution.&rdquo;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Neither
we nor the selling stockholder has authorized anyone to provide any information other than that contained or incorporated by reference
in this prospectus or in any related prospectus supplement or any free writing prospectus that we have authorized. We take no responsibility
for, and can provide no assurance as to the reliability of, any other information that others may give you. The shares are not being
offered in any jurisdiction where the offer is not permitted. You should not assume that the information contained in or incorporated
by reference in this prospectus is accurate as of any date other than the respective dates of such document. Our business, financial
condition, results of operations and prospects may have changed since those dates.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Throughout
this prospectus, the terms &ldquo;we,&rdquo; &ldquo;us,&rdquo; &ldquo;our,&rdquo; and our &ldquo;company&rdquo; refer to Qualigen Therapeutics,
Inc. and its subsidiaries.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 3; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->i<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="qg_002"></A>SPECIAL
NOTE REGARDING FORWARD-LOOKING STATEMENTS</B></FONT></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
prospectus and the documents we have filed with the SEC that are incorporated by reference contain &ldquo;forward-looking statements&rdquo;
within the meaning of Section 27A of the Securities Act of 1933, as amended (the &ldquo;Securities Act&rdquo;), and the Securities Exchange
Act of 1934, as amended (the &ldquo;Exchange Act&rdquo;). These statements relate to future events or to our future operating or financial
performance and involve known and unknown risks, uncertainties and other factors that may cause our actual results, performance or achievements
to be materially different from any future results, performances or achievements expressed or implied by the forward-looking statements.
Forward-looking statements may include, but are not limited to, statements about:</FONT></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 6%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 6%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 88%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    ability to successfully develop any drugs or therapeutic devices;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    ability to progress our drug candidates through preclinical and clinical development;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    ability to obtain the requisite regulatory approvals for our clinical trials and to begin and complete such trials according to any
    projected timeline;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    ability to complete enrollment in our clinical trials as contemplated by any projected timeline;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    likelihood that future clinical trial data will be favorable or that such trials will confirm any improvements over other products
    or lack negative impacts;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    ability to successfully commercialize any drugs;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    ability to procure or earn sufficient working capital to complete the development, testing and launch of our prospective therapeutic
    products;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    likelihood that patents will issue on our owned and in-licensed patent applications;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    ability to protect our intellectual property; and</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    ability to compete.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
some cases, you can identify forward-looking statements by terms such as &ldquo;anticipates,&rdquo; &ldquo;believes,&rdquo; &ldquo;could,&rdquo;
&ldquo;estimates,&rdquo; &ldquo;intends,&rdquo; &ldquo;may,&rdquo; &ldquo;plans,&rdquo; &ldquo;potential,&rdquo; &ldquo;will,&rdquo;
&ldquo;would,&rdquo; or the negative of these terms or other similar expressions. These statements reflect our current views with respect
to future events and are based on assumptions and are subject to risks and uncertainties. Given these uncertainties, you should not place
undue reliance on these forward-looking statements as predictions of future events. We discuss in greater detail many of these risks
in our most recent Annual Report on Form 10-K and in our most recent Quarterly Report on Form 10-Q, as well as any amendments thereto
reflected in subsequent filings with the SEC, which are incorporated by reference into this prospectus in their entirety. Also, these
forward-looking statements represent our estimates and assumptions only as of the date of the document containing the applicable statement.
Unless required by law, we undertake no obligation to update or revise any forward-looking statements to reflect new information or future
events or developments.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, statements that &ldquo;we believe&rdquo; and similar statements reflect our beliefs and opinions on the relevant subject. These
statements are based upon information available to us as of the date of this prospectus, and while we believe such information forms
a reasonable basis for such statements, such information may be limited or incomplete, and our statements should not be read to indicate
that we have conducted an exhaustive inquiry into, or review of, all potentially available relevant information. These statements are
inherently uncertain and investors are cautioned not to unduly rely upon these statements.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">You
should read this prospectus, together with the documents we have filed with the SEC that are incorporated by reference, any prospectus
supplement and any free writing prospectus that we may authorize completely and with the understanding that our actual future results
may be materially different from what we expect. We qualify all of the forward-looking statements in the foregoing documents by these
cautionary statements.</FONT></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 4; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->ii<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="qg_003"></A>PROSPECTUS
SUMMARY</B></FONT></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>This
summary highlights some information from this prospectus. It may not contain all the information important to making an investment decision.
You should read the following summary together with the more detailed information regarding our Company and the securities being sold
in this offering, including &ldquo;Risk Factors&rdquo; and other information incorporated by reference herein.</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Overview</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are a clinical stage therapeutics company focused on developing treatments for adult and pediatric cancers with potential for Orphan
Drug designation.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
cancer therapeutics pipeline includes QN-302, our Pan-RAS Inhibitor platform (formerly RAS-F) and QN-247.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
lead oncology therapeutics program, QN-302, is a small molecule selective transcription inhibitor with strong binding affinity to G4s
prevalent in cancer cells, which binding could, by stabilizing the G4s against &ldquo;unwinding,&rdquo; help inhibit cancer cell proliferation.
QN-302 has received Investigational New Drug (IND) clearance from the U.S. Food and Drug Administration (FDA) to proceed with its Phase
1 clinical trial. Earlier this year, QN-302 also received Orphan Drug Designation (ODD) from FDA for the indication of pancreatic cancer.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
Pan-RAS portfolio consists of a family of Pan-RAS oncogene protein-protein interaction inhibitor small molecules believed to inhibit
or block mutated RAS genes&rsquo; proteins from binding to their effector proteins. Preventing this binding could stop tumor growth,
especially in RAS-driven tumors such as pancreatic, colorectal and lung cancers.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
investigational QN-247 compound binds nucleolin, a key multi-functional regulatory phosphoprotein that is overexpressed in cancer cells.
Such binding could inhibit the cancer cells&rsquo; proliferation. The foundational aptamer of QN-247 is QN-165 (formerly referred to
as AS1411), which we have deprioritized as a drug candidate for treating COVID-19 and other viral-based infectious diseases. This is
conjugated to a Gold Nanoparticle (GNP).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Therapeutics
Pipeline</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><IMG SRC="form424b3_002.jpg" ALT="">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
lead drug compound QN-302 (formerly SOP1812) is being developed to target regulatory regions of cancer genes that down-regulate gene
expression in multiple cancer pathways for potential treatment of G4-targeted tumors (<I>e.g</I>., pancreatic cancer).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
investigational compounds within our Pan-RAS Inhibitor portfolio are designed to suppress the interaction of endogenous RAS with c-RAF,
upstream of the KRAS, HRAS and NRAS effector pathways, and is being developed for the potential treatment of RAS-driven tumors.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
anticancer drug candidate, QN-247 (formerly referred to as ALAN or AS1411-GNP) is aptamer-based and currently in development to treat
a variety of cancer types, including liquid and solid tumors.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 5; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
May 26, 2022, we acquired a 52.8% interest in NanoSynex, Ltd. (&ldquo;NanoSynex&rdquo;). NanoSynex is a micro-biologics diagnostic company
domiciled in Israel. NanoSynex&rsquo;s technology is an Antimicrobial Susceptibility Testing (AST) that aims to enable better targeting
of antibiotics for their most suitable uses to ultimately result in faster and more efficacious treatment, hence reducing hospitals mortality
and morbidity rates. As described below, we have recently reduced our ownership interest in NanoSynex to below 50%.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Recent
Developments</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>FDA
IND Clearance to Initiate Phase 1 Clinical Trial of QN-302</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
August 1, 2023, we announced that FDA has cleared our IND application for QN-302. Based on this clearance, we plan to initiate the Phase
1 clinical trial in the second half of 2023 and will enroll patients with advanced or metastatic solid tumors. The proposed Phase 1 clinical
trial is a multicenter, open-label, dose escalation, safety, pharmacokinetic, and pharmacodynamic study with dose expansion to evaluate
safety, tolerability, and antitumor activity of QN-302 in patients with advanced solid tumors that have not responded to or that have
recurred following treatment with available therapies. We anticipate the dosing of at least 24 patients in Phase 1a can be completed
in 2024, funded in part by proceeds received by the divestiture of the Company&rsquo;s diagnostics business in July 2023.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Sale
of Diagnostics Business</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
July 20, 2023, we sold all of the issued and outstanding shares of common stock of Qualigen, Inc., a wholly-owned subsidiary and the
legal entity operating our FastPack&trade; diagnostic business, to Chembio Diagnostics, Inc. (the &ldquo;Buyer&rdquo;), a subsidiary
of Biosynex, S.A. (the &ldquo;Transaction&rdquo;). As consideration for the shares of Qualigen, Inc., we received a cash payment of approximately
$4.7 million, which payment is subject to post-closing adjustments. An additional $450,000 was delivered by the Buyer to an escrow account
to satisfy our indemnification obligations. Any amounts remaining in the escrow account that have not been offset or reserved for claims
will be released to us within five business days following the date that is 18 months after the closing of the Transaction. Following
the consummation of the Transaction, Qualigen, Inc. became a wholly-owned subsidiary of the Buyer.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Amendment
and Settlement Agreement with NanoSynex Ltd.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
July 20, 2023, we entered into an Amendment and Settlement Agreement with NanoSynex (the &ldquo;NanoSynex Amendment&rdquo;), which amended
the Master Funding Agreement for the Operational and Technology Funding of Nanosynex Ltd., dated May 26, 2022, by and between us and
NanoSynex (the &ldquo;Original NanoSynex Agreement&rdquo;), to, among other things, provide for the further funding of NanoSynex, as
contemplated by the Original NanoSynex Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the terms of the NanoSynex Amendment, we agreed to advance to NanoSynex an aggregate amount of $1,610,000 as follows: (i) $380,000
within five business days of the execution of the NanoSynex Amendment, (ii) $560,000 on or before November 30, 2023, against which NanoSynex
will issue a promissory note to us with a face value in the amount of such funding, and (iii) $670,000 on or before March 31, 2024, against
which NanoSynex will issue a promissory note to us with a face value in the amount of such funding. The NanoSynex Amendment further provides
that the initial payment of $380,000 would be satisfied by our surrender of the 281,000 Preferred B Shares of NanoSynex then held by
us, and such share surrender has resulted in our ownership in NanoSynex being reduced from approximately 52.8% to approximately 49.97%
of the issued and outstanding voting equity of NanoSynex. The NanoSynex Amendment supersedes any payments contemplated by the Original
NanoSynex Agreement, such that except as described in the NanoSynex Amendment, we will have no further payment obligations to NanoSynex
under the Original NanoSynex Agreement or otherwise (including by way of equity investment, loan financing or credit lines).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 6; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Transaction
with the Selling Stockholder</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
December 21, 2022, we entered into a Securities Purchase Agreement (&ldquo;Agreement&rdquo;) with the selling stockholder, pursuant to
which, on December 22, 2022, we issued to the selling stockholder in a private placement (the &ldquo;Private Placement&rdquo;) an 8%
Senior Convertible Debenture (the &ldquo;Debenture&rdquo;) in the aggregate principal amount of $3,300,000 for a purchase price of $3,000,000.
The Debenture is convertible, at any time, and from time to time, at the selling stockholder&rsquo;s option, into shares of our common
stock, at a price equal to $1.32 per share, subject to adjustment as described in the Debenture (the &ldquo;Conversion Price&rdquo;)
and the other terms and conditions described in the Debenture, including our receipt of the necessary stockholder approvals, which we
obtained at our 2023 annual meeting of stockholders. As of August 31, 2023, the Debenture is convertible into 1,458,537 shares of our
common stock.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the terms of the Agreement, we also issued to the selling stockholder on December 22, 2022 a common stock purchase warrant (the &ldquo;Warrant&rdquo;)
to purchase up to 2,500,000 shares of our common stock (the &ldquo;Warrant Shares,&rdquo;), at a price of $1.65 per share, subject to
adjustment as described in the Warrant (the &ldquo;Exercise Price&rdquo;). The Warrant may be exercised, in whole or in part, at any
time on or after June 22, 2023 and before June 22, 2028, subject to the terms and conditions described in the Warrant, including our
receipt of the necessary stockholder approvals, which we obtained at our 2023 annual meeting of stockholders.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Commencing
June 1, 2023 and continuing on the first day of each month thereafter until the earlier of (i) December 22, 2025 (<I>i.e</I>., the Maturity
Date) and (ii) the full redemption of the Debenture (each such date, a &ldquo;Monthly Redemption Date&rdquo;), we will redeem $110,000
plus accrued but unpaid interest, liquidated damages and any amounts then owing under the Debenture (the &ldquo;Monthly Redemption Amount&rdquo;).
The Monthly Redemption Amount will be paid in cash; provided that after the first two monthly redemptions, we may elect to pay all or
a portion of a Monthly Redemption Amount in shares of our common stock, based on a conversion price equal to the lesser of (i) the then
Conversion Price of the Debenture and (ii) 85% of the average of the VWAPs (as defined in the Debenture) for the five consecutive trading
days ending on the trading day that is immediately prior to the applicable Monthly Redemption Date. We may also redeem some or all of
the then outstanding principal amount of the Debenture at any time for cash in an amount equal to 105% of the then outstanding principal
amount of the Debenture being redeemed plus accrued but unpaid interest, liquidated damages and any amounts then owing under the Debenture.
These monthly redemption and optional redemptions are subject to the satisfaction of the terms and conditions described in the Debenture,
including our receipt of the necessary stockholder approvals, which we obtained at our 2023 annual meeting of stockholders.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Debenture accrues interest at the rate of 8% per annum, which does not begin accruing until December 1, 2023, and will be payable on
a quarterly basis. Interest may be paid in cash or shares of our common stock or a combination thereof at our option; provided that interest
may only be paid in shares if the Equity Conditions (as defined in the Debenture) have been satisfied.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Both
the Debenture and the Warrant provide for adjustments to the Conversion Price and Exercise Price, respectively, in connection with stock
dividends and splits, subsequent equity sales and rights offerings, pro rata distributions, and certain fundamental transactions. Both
the Debenture and the Warrant include a beneficial ownership blocker of 9.99%, which may only be waived by the selling stockholder upon
61 days&rsquo; notice to us.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
issuance of the Debenture and the Warrant to the selling stockholder was exempt from the registration requirements of the Securities
Act pursuant to the exemption for transactions by an issuer not involving any public offering under Section 4(a)(2) of the Securities
Act.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the terms of the Agreement, we entered into a registration rights agreement with the selling stockholder on December 22, 2022 (the
&ldquo;Registration Rights Agreement&rdquo;), pursuant to which we agreed to file one or more registration statements, as necessary,
and to the extent permissible, to register under the Securities Act the resale of (a) all shares of our common stock issued and issuable
upon conversion in full of the Debenture (without regard to any conversion limitations therein), (b) all shares of our common stock issued
and issuable as interest or principal on the Debenture (assuming all permissible interest and principal payments are made in shares of
our common stock and the Debenture is held until maturity), (c) all Warrant Shares then issued and issuable upon exercise of the Warrant
(without regard to any exercise limitations therein), (d) any additional shares of our common stock issued and issuable in connection
with any anti-dilution provisions in the Debenture or the Warrant (in each case, without giving effect to any limitations on conversion
set forth in the Debenture or limitations on exercise set forth in the Warrant) and (e) any securities issued or then issuable upon any
stock split, dividend or other distribution, recapitalization or similar event with respect to the foregoing. Under the terms of the
Registration Rights Agreement, we agreed to use commercially reasonable efforts to keep the registration statement continuously effective
under the Securities Act until the earliest date that all Registrable Securities (as defined in the Registration Rights Agreement) covered
by such registration statement (i) have been sold, thereunder or pursuant to Rule 144, or (ii) may be sold without volume or manner-of-sale
restrictions pursuant to Rule 144 and without the requirement for us to be in compliance with the current public information requirement
under Rule 144, as determined by our counsel pursuant to a written opinion letter to such effect, addressed and acceptable to our transfer
agent.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 7; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Reverse
Stock Split</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Effective
as of November 23, 2022, we completed a 1-for-10 reverse stock split of our common stock in order to regain compliance with Nasdaq Listing
Rule 5550(a)(2), which requires a minimum bid price of $1.00 per share. As a result of the reverse stock split, each 10 shares of our
common stock issued and outstanding as of 12:01 a.m. Eastern Time on November 23, 2022 were combined and converted into one share of
common stock. On December 9, 2022, we received written notice from the Listing Qualifications Department of The Nasdaq Stock Market LLC
stating that because our shares of common stock had a closing bid price at or above $1.00 per share for a minimum of 10 consecutive business
days, the Company has regained compliance with the minimum bid price requirement of $1.00 per share for continued listing on The Nasdaq
Capital Market, as set forth in Nasdaq Listing Rule 5550(a)(2), and that the matter is now closed. All references to numbers of shares
of Common Stock and per-share information in this prospectus have been adjusted retroactively, as appropriate, to reflect the 1-for-10
reverse stock split.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Corporate
Background</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Ritter
Pharmaceuticals, Inc. (our predecessor) was formed as a Nevada limited liability company on March 29, 2004 under the name Ritter Natural
Sciences, LLC. In September 2008, this company converted into a Delaware corporation under the name Ritter Pharmaceuticals, Inc. On May
22, 2020, upon completing a &ldquo;reverse recapitalization&rdquo; transaction with Qualigen, Inc., Ritter Pharmaceuticals, Inc. was
renamed Qualigen Therapeutics, Inc. Qualisys Diagnostics, Inc. was formed as a Minnesota corporation in 1996, reincorporated to become
a Delaware corporation in 1999, and then changed its name to Qualigen, Inc. in 2000. Qualigen, Inc. was a wholly-owned subsidiary of
the Company. On July 20, 2023, we sold all of the issued and outstanding shares of common stock of Qualigen, Inc. to Chembio Diagnostics,
Inc. (&ldquo;Chembio&rdquo;), a wholly-owned subsidiary of Biosynex, S.A. Following the consummation of this transaction, Qualigen, Inc.
became a wholly-owned subsidiary of Chembio.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
principal executive offices are located at 5857 Owens Avenue, Suite 300, Carlsbad, CA 92008. Our telephone number is (760) 452-8111.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 8; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="qg_004"></A>THE
OFFERING</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; width: 28%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Issuer</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 70%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Qualigen
    Therapeutics, Inc.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Common
    stock offered by the selling stockholder</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3,958,537
    shares issuable upon exercise of the Debenture and the Warrants (the &ldquo;Resale Shares&rdquo;).</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Terms
    of the offering</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    selling stockholder and any of its pledgees, assignees and successors-in-interest may, from time to time, sell any or all of their
    shares covered hereby on Nasdaq or any other stock exchange, market or trading facility on which the shares are traded or in private
    transactions. These sales may be at fixed or negotiated prices. See &ldquo;Plan of Distribution.&rdquo;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Common
    stock to be outstanding after this offering</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">9,011,000
    shares.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Use
    of proceeds</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
    will not receive any of the proceeds from the sale of our common stock by the selling stockholder pursuant to this prospectus. However,
    we will receive the proceeds of any cash exercise of the Warrants. If all of the Warrants were exercised for cash, we would receive
    aggregate proceeds of approximately $4.1 million. We expect to use any proceeds received by us from the cash exercise of Warrants
    to advance our QN-302 Investigative New Drug candidate towards clinical trials and for other working capital purposes.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Nasdaq
    Capital Market symbol</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">QLGN</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Risk
    factors</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Investing
    in our securities involves a high degree of risk. See &ldquo;Risk Factors&rdquo; on page 5 of this prospectus to read about factors
    that you should consider carefully before buying our securities.</FONT></TD></TR>
  </TABLE>
<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
number of shares of common stock to be outstanding after this offering is based on 5,052,463 shares of common stock outstanding on August
31, 2023, includes all of the Resale Shares, and excludes:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 48px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top; width: 49px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">439,549
    shares of common stock issuable upon the exercise of options outstanding as of August 31, 2023, at a weighted average exercise price
    of $35.05 per share;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,619,934
    shares of common stock issuable upon the exercise of warrants outstanding as of August 31, 2023, at a weighted average exercise price
    of $3.15 per share, excluding the Warrants;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">316,153
    shares of common stock available for future issuance under our 2020 Stock Equity Incentive Plan (as amended, the &ldquo;2020 Plan&rdquo;),
    as of August 31, 2023; and</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">100,000
    shares of common stock available for future issuance under the 2022 Employee Stock Purchase Plan (the &ldquo;ESPP&rdquo;) as of August
    31, 2023, which plan has been temporarily suspended.</FONT></TD></TR>
  </TABLE>
<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Unless
otherwise indicated, all information in this prospectus gives effect to the 1-for-10 reverse stock split effectuated on November 23,
2022.</FONT></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 9; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="qg_005"></A>RISK
FACTORS</B></FONT></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Investing
in our securities involves a high degree of risk. You should carefully consider the risks described in the documents incorporated by
reference in this prospectus and any prospectus supplement, as well as other information we include or incorporate by reference into
this prospectus and any applicable prospectus supplement, before making an investment decision. Our business, financial condition or
results of operations could be materially adversely affected by the materialization of any of these risks. The trading price of our securities
could decline due to the materialization of any of these risks, and you may lose all or part of your investment. This prospectus and
the documents incorporated herein by reference also contain forward-looking statements that involve risks and uncertainties. Actual results
could differ materially from those anticipated in these forward-looking statements as a result of certain factors, including the risks
described in the documents incorporated herein by reference, including our Annual Report on Form 10-K for the fiscal year ended December
31, 2022, filed with the SEC on May 2, 2023, as amended on July 7, 2023, our most recent quarterly report on Form 10-Q for the fiscal
quarter ended June 30, 2023 filed with the SEC on August 14, 2023, our current reports on Form 8-K and other documents we file with the
SEC from time to time that are deemed incorporated by reference into this prospectus.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>The
sale of a substantial number of our shares of common stock in the public market, including resale of the Resale Shares issued to the
selling stockholder, could adversely affect the prevailing market price for our common stock and result in dilution to our stockholders.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are registering for resale up to 3,958,537 Resale Shares issuable to the selling stockholder upon the conversion of the Debenture and
exercise of the Warrant. Sales of substantial amounts of our shares of common stock in the public market, or the perception that such
sales might occur, could adversely affect the market price of our common stock. We cannot predict if and when the selling stockholder
may sell such shares in the public market. Furthermore, in the future, we may issue additional shares or other equity or debt securities
exercisable for, or convertible into, our common stock. To the extent that additional shares are issued or convertible securities are
exercised or converted, our stockholders will experience dilution. We may also consider from time to time various strategic alternatives
that could involve issuances of additional shares, including but not limited to acquisitions and business combinations, but do not currently
have any definitive plans to enter into any of these transactions.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 10; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="qg_006"></A>USE
OF PROCEEDS</B></FONT></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
will not receive any of the proceeds from the sale of shares of our common stock in this offering. The selling stockholder will receive
all of the proceeds from the sale of shares of common stock hereunder.</FONT></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
may, however, receive cash proceeds equal to the exercise price of the Warrants that the selling stockholder may exercise, to the extent
any such Warrants are exercised for cash. The Warrants may be exercised, in whole or in part, for cash or by means of cashless exercise
if, at the time of exercise, there is no effective registration statement registering, or the prospectus contained therein is not available
for, the resale of the Warrant Shares by the selling stockholder. If all of the Warrants are exercised for cash, then we will receive
gross proceeds of approximately $4.1 million, subject to any adjustments. We expect to use any proceeds received by us from the cash
exercise of these Warrants to advance our QN-302 Investigative New Drug candidate towards clinical trials and for other working capital
purposes.</FONT></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 11; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="qg_007"></A>SELLING
STOCKHOLDER</B></FONT></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have prepared this prospectus to allow the selling stockholder to offer and sell from time to time up to an aggregate of 3,958,537 Resale
Shares for its own account, consisting of (i) 1,458,537 shares of our common stock issuable upon conversion of the Debenture, based on
the initial conversion price of $1.32, and (iii) 2,500,000 Warrant Shares issuable upon exercise of the Warrant (without regard to any
exercise limitations therein) at the initial exercise price of $1.65.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are registering the offer and sale of the Resale Shares to satisfy certain registration rights that we granted the selling stockholder
in connection with the issuance of the Debenture and the Warrant.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table sets forth (i) the name of the selling stockholder, (ii) the number of shares beneficially owned by the selling stockholder,
(iii) the number of Resale Shares that may be offered under this prospectus, and (iv) the number of shares of our common stock to be
beneficially owned by the selling stockholder after the offering assuming all of the Resale Shares covered by this prospectus are sold.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
number of shares of common stock set forth in the following table for the selling stockholder does not take into account the exercise
limitations set forth in the Debenture and the Warrant, or the fact that the conversion price of the Debenture and the exercise price
of the Warrant may be adjusted from time to time in accordance with their terms. As a result, the actual number of Resale Shares that
may be issued to and sold by the selling stockholder could be materially less or more than the estimated numbers in the column titled
&ldquo;Number of Shares Being Offered&rdquo; depending on factors which cannot be predicted by us at this time. In addition, we do not
know how long the selling stockholder will hold the Resale Shares before selling them, and we currently have no agreements, arrangements
or understandings with the selling stockholder regarding the sale or other disposition of any Resale Shares.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Except
as described in this prospectus, the selling stockholder does not have, nor has it had during the three years prior to the date of this
prospectus, any position, office or other material relationships with us or any of our predecessors or affiliates. To our knowledge,
except as set forth in the table below, the selling stockholder is not a broker-dealer or affiliated with a broker-dealer, nor at the
time of the acquisition of the Debenture and the Warrant did it have direct or indirect agreements or understandings with any person
to distribute any common stock, including the Resale Shares.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
information set forth in the table below is based upon information obtained from the selling stockholder. Beneficial ownership of the
selling stockholder is determined in accordance with Rule 13d-3(d) under the Exchange Act. The percentages of shares beneficially
owned prior to and after the offering are based on 5,052,463 shares of our common stock outstanding as of August 31, 2023,
and gives effect to the issuance of an aggregate of 3,958,537 Resale Shares.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
the terms of the Debenture and the Warrants, the selling stockholder may not exercise the Debenture or the Warrants to the extent such
exercise would cause such selling stockholder, together with its affiliates, to beneficially own a number of shares which would exceed
9.99% of our then outstanding shares following such conversion or exercise, excluding for purposes of such determination shares not yet
issued. The number of ordinary shares reflected in the table does not reflect this limitation.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
used in this prospectus, the term &ldquo;selling stockholder&rdquo; includes the selling stockholder listed in the table below, together
with any additional selling stockholder listed in a prospectus supplement, and their donees, pledgees, assignees, transferees, distributees
and successors-in-interest that receive Resale Shares in any non-sale transfer after the date of this prospectus.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 11pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="6" STYLE="border-bottom: Black 1.5pt solid; text-align: center"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><BR><BR><B>Shares
                                            of Common Stock Beneficially Owned</B></FONT></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Prior
                                            to this Offering</B></FONT></P></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font-size: 11pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-size: 11pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Number
    of Shares Being Offered</B></FONT></TD><TD STYLE="font-size: 11pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="6" STYLE="border-bottom: Black 1.5pt solid; text-align: center"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Shares
                                            of Common Stock Beneficially Owned</B></FONT></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>After
                                            this Offering</B></FONT></P></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name
    of Selling Stockholder</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-size: 11pt; font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-size: 11pt; font-weight: bold; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Number<SUP>(1)</SUP></B></FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-size: 11pt; font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Percent</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="padding-bottom: 1.5pt; text-align: center"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"></P></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-size: 11pt; font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-size: 11pt; font-weight: bold; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Number<SUP>(2)</SUP></B></FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-size: 11pt; font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Percent</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 35%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Alpha Capital
    Anstalt</FONT></TD><TD STYLE="width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="width: 9%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4,072,840</FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="width: 9%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">44.75</FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</FONT></TD><TD STYLE="width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="width: 9%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3,958,537</FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="width: 9%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">114,303</FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="width: 9%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.26</FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">%</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">(1) <FONT STYLE="background-color: white">Includes (i) <FONT STYLE="background-color: white">22,985
shares of common stock held by the selling stockholder, (ii) </FONT> 3,958,537 Resale Shares issuable to the selling stockholder pursuant
to the conversion of the Debenture and the exercise of the Warrant<FONT STYLE="background-color: white">,</FONT> and (ii<FONT STYLE="background-color: white">i</FONT>) 91,318 shares of common stock issuable upon
the exercise of warrants held by the selling stockholder prior to the Private Placement which will continue to be held by the
selling stockholder after this offering, assuming (i) none of the aforementioned warrants or the Warrant is exercised by means of
the cashless exercise, and (ii) none of the limitations on the conversion of the Debenture and on exercise of the Warrant, as set
forth therein, apply.</FONT> The address of Alpha Capital Anstalt is Altenbach 8, 9490 Vaduz, Liechtenstein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">(2) <FONT STYLE="background-color: white">Assumes
the sale of all shares of common stock being offered pursuant to this prospectus</FONT>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 12; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="qg_008"></A>PLAN
OF DISTRIBUTION</B></FONT></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are registering the Resale Shares that may be issued to the selling stockholder pursuant to the terms of the Debenture and the Warrant
to permit the resale of these Resale Shares by the selling stockholder from time to time after the date of this prospectus. We will not
receive any of the proceeds from the sale of Resale Shares by the selling stockholder, other than the exercise price of the Warrant if
paid in cash.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
selling stockholder and any of its donees, pledgees, assignees and successors-in-interest may, from time to time, sell, transfer or otherwise
dispose of any or all of the Resale Shares covered hereby on the principal trading market or any other stock exchange, market or trading
facility on which our common stock is then traded or in private transactions. These dispositions may be at fixed prices, at prevailing
market prices at the time of sale, at prices related to the prevailing market price, at varying prices determined at the time of sale,
or at negotiated prices. The selling stockholder may use any one or more of the following methods when selling securities:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 6%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 6%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 88%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ordinary
    brokerage transactions and transactions in which the broker-dealer solicits purchasers;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">block
    trades in which the broker-dealer will attempt to sell the Resale Shares as agent but may position and resell a portion of the block
    as principal to facilitate the transaction;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">purchases
    by a broker-dealer as principal and resale by the broker-dealer for its own account;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">an
    exchange distribution in accordance with the rules of the applicable exchange;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">privately
    negotiated transactions;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">settlement
    of short sales;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">in
    transactions through broker-dealers that agree with the Selling Stockholder to sell a specified number of such securities at a stipulated
    price per security;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">through
    the writing or settlement of options or other hedging transactions, whether through an options exchange or otherwise;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a
    combination of any such methods of sale; or</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">any
    other method permitted pursuant to applicable law.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
selling stockholder may also sell the Resale Shares under Rule 144 or any other exemption from registration under the Securities Act,
if available, rather than under this prospectus.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Broker-dealers
engaged by the selling stockholder may arrange for other brokers-dealers to participate in sales. Broker-dealers may receive commissions
or discounts from the selling stockholder (or, if any broker-dealer acts as agent for the purchaser of securities, from the purchaser)
in amounts to be negotiated, but, except as set forth in a supplement to this prospectus, in the case of an agency transaction not in
excess of a customary brokerage commission in compliance with FINRA Rule 2121; and in the case of a principal transaction a markup or
markdown in compliance with FINRA Rule 2121. In connection with the sale of the Resale Shares or interests therein, the selling stockholder
may enter into hedging transactions with broker-dealers or other financial institutions, which may in turn engage in short sales of the
Resale Shares in the course of hedging the positions they assume. The selling stockholder may also sell the Resale Shares short and deliver
the Resale Shares to close out its short positions, or loan or pledge the Resale Shares to broker-dealers that in turn may sell the Resale
Shares. The selling stockholder may also enter into option or other transactions with broker-dealers or other financial institutions
or create one or more derivative securities which require the delivery to such broker-dealer or other financial institution of the Resale
Shares offered by this prospectus, which Resale Shares such broker-dealer or other financial institution may resell pursuant to this
prospectus (as supplemented or amended to reflect such transaction).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 13; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
selling stockholder may, from time to time, pledge or grant a security interest in some or all of the Resale Shares owned by it and,
if it defaults in the performance of its secured obligations, the pledgees or secured parties may offer and sell the Resale Shares, from
time to time, under this prospectus, or under an amendment to the registration statement of which this prospectus forms a part amending
the list of selling stockholder to include the pledgee, transferee or other successors in interest as selling stockholders under this
prospectus. The selling stockholder may also transfer the Resale Shares in other circumstances, in which case the pledgees, transferees
or other successors in interest will be the selling beneficial owners for purposes of this prospectus.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
selling stockholder and any broker-dealers or agents that are involved in selling the Resale Shares may be deemed to be &ldquo;underwriters&rdquo;
within the meaning of Section 2(11) of the Securities Act in connection with such sales. In such event, any discounts, commissions, concessions
or profits received by such broker-dealers or agents and any profit on the resale of the Resale Shares purchased by them may be deemed
to be underwriting commissions or discounts under the Securities Act. Selling stockholders who are &ldquo;underwriters&rdquo; within
the meaning of Section 2(11) of the Securities Act will be subject to the prospectus delivery requirements of the Securities Act. The
selling stockholder has informed us that it does not have any written or oral agreement or understanding, directly or indirectly, with
any person to distribute the Resale Shares.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
the extent required, the Resale Shares to be sold, the names of the selling stockholder, the respective purchase prices and public offering
prices, the names of any agents, dealer or underwriter, and any applicable commissions or discounts with respect to a particular offer
will be set forth in an accompanying prospectus supplement or, if appropriate, a post-effective amendment to the registration statement
that includes this prospectus.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Resale Shares will be sold only through registered or licensed brokers or dealers if required under applicable state securities laws.
In addition, in certain states, the Resale Shares covered hereby may not be sold unless they have been registered or qualified for sale
in the applicable state or an exemption from the registration or qualification requirement is available and is complied with.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are required to pay certain fees and expenses incurred by us incident to the registration of the Resale Shares. Discounts, concessions,
commissions and similar selling expenses attributable to the sale of Resale Shares covered by this prospectus will be borne by the selling
stockholder. We have agreed to indemnify the selling stockholder against certain losses, claims, damages and liabilities, including liabilities
under the Securities Act, relating to the registration of the Resale Shares offered by this prospectus.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
agreed to keep this prospectus effective until the earlier of (i) the date on which the securities may be resold by the selling stockholder
without registration and without regard to any volume or manner-of-sale limitations by reason of Rule 144, without the requirement for
us to be in compliance with the current public information under Rule 144 under the Securities Act or (ii) all of the securities have
been sold pursuant to this prospectus or Rule 144 under the Securities Act.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
applicable rules and regulations under the Exchange Act, any person engaged in the distribution of the Resale Shares may not simultaneously
engage in market making activities with respect to the Resale Shares for the applicable restricted period, as defined in Regulation M,
prior to the commencement of the distribution. In addition, the selling stockholder will be subject to applicable provisions of the Exchange
Act and the rules and regulations thereunder, including Regulation M, which may limit the timing of purchases and sales of the Resale
Shares by the selling stockholder or any other person.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
will make copies of this prospectus available to the selling stockholder for the purpose of satisfying the requirement to deliver a copy
of this prospectus to each purchaser at or prior to the time of the sale (including by compliance with Rule 172 under the Securities
Act).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 14; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="qg_009"></A>DESCRIPTION
OF OUR CAPITAL STOCK</B></FONT></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>The
following description of the terms of our securities is not complete and is qualified in its entirety by reference to our Certificate
of Incorporation, and our amended and restated bylaws (the &ldquo;Bylaws&rdquo;), both of which are filed as exhibits to our Annual Report
on Form 10-K.</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
our Certificate of Incorporation and Bylaws, we are authorized to issue 240,000,000 shares of capital stock, consisting of 225,000,000
shares of common stock, par value $0.001 per share, and 15,000,000 shares of preferred stock, $0.001 par value per share, including 7,000
shares that have been designated as Series Alpha Preferred Stock. As of August 31, 2023, there were 5,052,463 shares of our common stock
outstanding and no shares of our Series Alpha Preferred Stock outstanding.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Common
Stock</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the terms of our Certificate of Incorporation, the holders of common stock are entitled to one vote per share on all matters to be
voted upon by the stockholders, except on matters relating solely to terms of preferred stock. Subject to preferences that may be applicable
to any outstanding preferred stock, the holders of common stock will be entitled to receive ratably such dividends, if any, as may be
declared from time to time by our Board of Directors out of funds legally available therefor. In the event of liquidation, dissolution
or winding up, the stockholders will be entitled to share ratably in all assets remaining after payment of liabilities, subject to prior
distribution rights of preferred stock, if any, then outstanding. The holders of our common stock will have no preemptive or conversion
rights or other subscription rights. There will be no redemption or sinking fund provisions applicable to our common stock.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Preferred
Stock</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the terms of our Certificate of Incorporation, our Board of Directors has the authority to issue preferred stock in one or more classes
or series and to fix the designations, powers, preferences and rights, and the qualifications, limitations or restrictions thereof, including
dividend rights, conversion right, voting rights, terms of redemption, liquidation preferences and the number of shares constituting
any class or series, without further vote or action by the stockholders.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
issuance of shares of preferred stock, or the issuance of rights to purchase such shares, may decrease the amount of earnings and assets
available for distribution to the holders of common stock, could adversely affect the rights and powers, including voting rights, of
the common stock, and could have the effect of delaying, deterring or preventing a change of control of us or an unsolicited acquisition
proposal.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Stock
Options</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of August 31, 2023, we had outstanding options to acquire 439,549 shares of our common stock, having a weighted-average exercise price
of $35.05 per share.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Warrants</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of August 31, 2023, we had outstanding warrants to purchase an aggregate of 4,119,934 shares of our common stock, having a weighted-average
exercise price of $2.24 per share.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Debenture</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Debenture held by the selling stockholder has a maturity date of December 22, 2025 and is convertible, at any time, and from time to
time, until the Debenture is no longer outstanding, at the selling stockholder&rsquo;s option, into shares of our common stock, at a
price equal to $1.32 per share, subject to adjustment as described in the Debenture and other terms and conditions described in the Debenture,
including our receipt of the necessary stockholder approvals, which we obtained at our 2023 annual meeting of stockholders.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 15; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Between
January 9 and 12, 2023, the Company issued 841,726 shares of common stock upon the selling stockholder&rsquo;s partial conversion of
the Debenture at $1.32 per share for a total of $1,111,078 principal. As of August 31, 2023, the Company paid an aggregate of $330,000
as the Monthly Redemption Amounts (as defined below) under the Debenture in cash for June, July and August. As of August 31, 2023, the
Debenture was convertible into 1,458,537 shares of our common stock. The Debenture includes a beneficial ownership blocker of 9.99%,
which may only be waived by the selling stockholder upon 61 days&rsquo; notice to us.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
at any time while the Debenture is outstanding, we or any of our subsidiaries as listed in the Agreement, as applicable, sells or grants
any option to purchase or sells or grants any right to reprice, or otherwise disposes of or issues (or announces any sale, grant or any
option to purchase or other disposition), any shares of our common stock or common stock equivalents entitling any person to acquire
shares of our common stock (the &ldquo;Common Stock Equivalents&rdquo;) at an effective price per share that is lower than the then Conversion
Price (such lower price, the &ldquo;Base Conversion Price&rdquo; and such issuances, collectively, a &ldquo;Dilutive Issuance&rdquo;),
then simultaneously with the consummation (or, if earlier, the announcement) of each Dilutive Issuance, the Conversion Price will be
reduced to equal the Base Conversion Price, provided that the Base Conversion Price will not be less than $0.260 (subject to adjustment
for reverse and forward stock splits, recapitalizations and similar transactions following the date of the Agreement).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Commencing
June 1, 2023 and continuing on each Monthly Redemption Date until the earlier of (i) December 22, 2025 (<I>i.e</I>., the Maturity Date)
and (ii) the full redemption of the Debenture, we will redeem $110,000 plus accrued but unpaid interest, liquidated damages and any amounts
then owing under the Debenture (the &ldquo;Monthly Redemption Amount&rdquo;). The Monthly Redemption Amount will be paid in cash; provided
that after the first two monthly redemptions, we may elect to pay all or a portion of a Monthly Redemption Amount in shares of our common
stock, based on a conversion price equal to the lesser of (i) the then Conversion Price of the Debenture and (ii) 85% of the average
of the VWAPs (as defined in the Debenture) for the five consecutive trading days ending on the trading day that is immediately prior
to the applicable Monthly Redemption Date. We may also redeem some or all of the then outstanding principal amount of the Debenture at
any time for cash in an amount equal to 105% of the then outstanding principal amount of the Debenture being redeemed plus accrued but
unpaid interest, liquidated damages and any amounts then owing under the Debenture. These monthly redemption and optional redemptions
are subject to the satisfaction of the terms and conditions described in the Debenture, including our receipt of the necessary stockholder
approvals, which we obtained at our 2023 annual meeting of stockholders.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Debenture accrues interest at the rate of 8% per annum, which does not begin accruing until December 1, 2023, and will be payable on
a quarterly basis. Interest may be paid in cash or shares of our common stock or a combination thereof at our option; provided that interest
may only be paid in shares if the Equity Conditions (as defined in the Debenture) have been satisfied.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Except
as otherwise set forth in the Debenture, we may not prepay any portion of the principal amount of the Debenture without the selling stockholder&rsquo;s
prior written consent.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Registration
Rights</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
entered into a registration rights agreement with the selling stockholder in December 2022 (the &ldquo;Registration Rights Agreement&rdquo;),
pursuant to which we agreed to file one or more registration statements, as necessary, and to the extent permissible, to register under
the Securities Act the resale of (a) all shares of our common stock issued and issuable upon conversion in full of the Debenture (without
regard to any conversion limitations therein), (b) all shares of our common stock issued and issuable as interest or principal on the
Debenture (assuming all permissible interest and principal payments are made in shares of our common stock and the Debenture is held
until maturity), (c) all Warrant Shares then issued and issuable upon exercise of the Warrant (without regard to any exercise limitations
therein), (d) any additional shares of our common stock issued and issuable in connection with any anti-dilution provisions in the Debenture
or the Warrant (in each case, without giving effect to any limitations on conversion set forth in the Debenture or limitations on exercise
set forth in the Warrant) and (e) any securities issued or then issuable upon any stock split, dividend or other distribution, recapitalization
or similar event with respect to the foregoing. Under the terms of the Registration Rights Agreement, we agreed to use commercially reasonable
efforts to keep the registration statement continuously effective under the Securities Act until the earliest date that all Registrable
Securities covered by such registration statement (i) have been sold, thereunder or pursuant to Rule 144, or (ii) may be sold without
volume or manner-of-sale restrictions pursuant to Rule 144 and without the requirement for us to be in compliance with the current public
information requirement under Rule 144, as determined by our counsel pursuant to a written opinion letter to such effect, addressed and
acceptable to our transfer agent.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
filed a resale registration statement on Form S-3 pursuant to the requirements of the Registration Rights Agreement on December 2022
(File Number 333-269088), which registration statement was declared effective by the SEC on January 5, 2023, and are now filing this
post-effective amendment to the registration statement, of which this prospectus forms a part.</FONT></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 16; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Anti-Takeover
Effects of Delaware Law and Our Certificate of Incorporation and Bylaws</B></FONT></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
provisions of Delaware law and our Certificate of Incorporation and Bylaws could discourage or make it more difficult to accomplish a
proxy contest or other change in our management or the acquisition of control by a holder of a substantial amount of our voting stock.
It is possible that these provisions could make it more difficult to accomplish, or could deter, transactions that stockholders may otherwise
consider to be in their best interests or in our best interests. These provisions are intended to enhance the likelihood of continuity
and stability in the composition of our board of directors and in the policies formulated by the board of directors and to discourage
certain types of transactions that may involve an actual or threatened change of our control. These provisions are designed to reduce
our vulnerability to an unsolicited acquisition proposal and to discourage certain tactics that may be used in proxy fights. Such provisions
also may have the effect of preventing changes in our management.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Delaware
Statutory Business Combinations Provision</I>. We are subject to the anti-takeover provisions of Section 203 of the Delaware General
Corporation Law (the &ldquo;DGCL&rdquo;). Section 203 prohibits a publicly-held Delaware corporation from engaging in a &ldquo;business
combination&rdquo; with an &ldquo;interested stockholder&rdquo; for a period of three years after the date of the transaction in which
the person became an interested stockholder, unless the business combination is, or the transaction in which the person became an interested
stockholder was, approved in a prescribed manner or another prescribed exception applies. For purposes of Section 203, a &ldquo;business
combination&rdquo; is defined broadly to include a merger, asset sale or other transaction resulting in a financial benefit to the interested
stockholder, and, subject to certain exceptions, an &ldquo;interested stockholder&rdquo; is a person who, together with his or her affiliates
and associates, owns, or within three years prior, did own, 15% or more of the corporation&rsquo;s voting stock.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Election
and Removal of Directors</I>. Except as may otherwise be provided by the DGCL, any director or the entire board of directors may be removed,
with or without cause, at an annual meeting or a special meeting called for that purpose, by the holders of a majority of the shares
then entitled to vote at an election of directors, provided a quorum is present. Vacancies on our board of directors resulting from the
removal of directors and newly created directorships resulting from any increase in the number of directors may be filled solely by the
affirmative vote of a majority of the remaining directors then in office (although less than a quorum) or by the sole remaining director.
This system of electing and removing directors may discourage a third party from making a tender offer or otherwise attempting to obtain
control of us, because it generally makes it more difficult for stockholders to replace a majority of our directors. Our Certificate
of Incorporation and Bylaws do not provide for cumulative voting in the election of directors.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Advance
Notice Provisions for Stockholder Proposals and Stockholder Nominations of Directors</I>. Our Bylaws provide that, for nominations to
the board of directors or for other business to be properly brought by a stockholder before a meeting of stockholders, the stockholder
must first have given timely notice of the proposal in writing to our Secretary. For an annual meeting, a stockholder&rsquo;s notice
generally must be delivered not less than 90 days or more than 120 days before the anniversary of the previous year&rsquo;s annual meeting.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Special
Meetings of Stockholders</I>. Special meetings of the stockholders may be called at any time only by the board of directors, the Chairman
of the board of directors, the Chief Executive Officer or the President, subject to the rights of the holders of any series of preferred
stock then outstanding.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Blank-Check
Preferred Stock</I>. Our board of directors is authorized to issue, without stockholder approval, preferred stock, the rights of which
will be determined at the discretion of the board of directors and that, if issued, could operate as a &ldquo;poison pill&rdquo; to dilute
the stock ownership of a potential hostile acquirer to prevent an acquisition that our board of directors does not approve.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Transfer
Agent</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
transfer agent and registrar for our common stock is Equiniti Trust Company. Its address is P.O. Box 64945, Saint Paul MN 55164-0945
and its telephone number is (800) 468-9716.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Listing</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
common stock is listed on The Nasdaq Capital Market under the symbol &ldquo;QLGN.&rdquo;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 17; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="qg_010"></A>LEGAL
MATTERS</B></FONT></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Reed
Smith LLP, Los Angeles, California, will pass upon the validity of the shares of common stock offered hereby.</FONT></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="qg_011"></A>EXPERTS</B></FONT></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
consolidated financial statements of Qualigen Therapeutics, Inc. for the year ended December 31, 2022 incorporated in this Registration
Statement and Prospectus have been so incorporated in reliance on the report of Baker Tilly US, LLP, an independent registered public
accounting firm, given on the authority of said firm as experts in auditing and accounting.</FONT></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="qg_012"></A>WHERE
YOU CAN FIND ADDITIONAL INFORMATION</B></FONT></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have filed with the SEC a registration statement on Form S-1 under the Securities Act for the shares of common stock, pre-funded warrants
and accompanying common stock warrants being offered by this prospectus. This prospectus, which is part of the registration statement,
does not contain all of the information included in the registration statement and the exhibits. For further information about us and
the common stock, pre-funded warrants and accompanying common warrants offered by this prospectus, you should refer to the registration
statement and its exhibits. References in this prospectus to any of our contracts or other documents are not necessarily complete, and
you should refer to the exhibits attached to the registration statement for copies of the actual contract or document. Additionally,
we file annual, quarterly and current reports, proxy statements and other information with the SEC.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
SEC maintains an internet site that contains reports, proxy and information statements and other information regarding issuers that file
electronically with the SEC, including us, at http://www.sec.gov. We make available, free of charge, on our website at www.qlgntx.com,
our annual reports on Form 10-K, quarterly reports on Form 10-Q, current reports on Form 8-K and amendments to those reports and statements
as soon as reasonably practicable after they are filed with the SEC. The contents of our and the SEC&rsquo;s websites are not part of
this prospectus, and the reference to our and the SEC&rsquo;s websites do not constitute incorporation by reference into this prospectus
of the information contained at those sites, other than documents we file with the SEC that are specifically incorporated by reference
into this prospectus.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 18; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="qg_013"></A>INCORPORATION
OF CERTAIN INFORMATION BY REFERENCE</B></FONT></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
SEC allows us to &ldquo;incorporate by reference&rdquo; information from other documents that we file with it, which means that we can
disclose important information to you by referring you to those documents. The information incorporated by reference is considered to
be part of this prospectus. Information in this prospectus supersedes information incorporated by reference that we filed with the SEC
prior to the date of this prospectus, while information that we file later with the SEC will automatically update and supersede the information
in this prospectus. We incorporate by reference into this prospectus and the registration statement of which this prospectus is a part
the information or documents listed below that we have filed with the SEC (Commission File No. 001-37428):</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 6%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 6%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 88%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
    Annual Report on <A HREF="https://www.sec.gov/ix?doc=/Archives/edgar/data/1460702/000149315223015184/form10-k.htm" STYLE="-sec-extract: exhibit">Form 10-K</A> for the fiscal year ended December 31, 2022, as filed with the SEC on May 2, 2023, as amended on <A HREF="https://www.sec.gov/ix?doc=/Archives/edgar/data/1460702/000149315223024027/form10-ka.htm" STYLE="-sec-extract: exhibit">Form 10-K/A</A> filed on July 7, 2023;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
    Quarterly Reports on Form 10-Q for the quarterly periods ended <A HREF="https://www.sec.gov/Archives/edgar/data/1460702/000149315223017315/form10-q.htm" STYLE="-sec-extract: exhibit">March 31, 2023</A> and <A HREF="https://www.sec.gov/Archives/edgar/data/1460702/000149315223028465/form10-q.htm" STYLE="-sec-extract: exhibit">June 30, 2023</A>, as filed with the SEC on May 15,
    2023 and August 14, 2023, respectively; </FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
    Current Reports on Form 8-K filed with the SEC on <A HREF="https://www.sec.gov/Archives/edgar/data/1460702/000149315223001067/form8-k.htm" STYLE="-sec-extract: exhibit">January 10, 2023</A>, <A HREF="https://www.sec.gov/Archives/edgar/data/1460702/000149315223002034/form8-k.htm" STYLE="-sec-extract: exhibit">January 20, 2023</A>, <A HREF="https://www.sec.gov/Archives/edgar/data/1460702/000149315223013314/form8-k.htm" STYLE="-sec-extract: exhibit">April 24, 2023</A>, <A HREF="https://www.sec.gov/Archives/edgar/data/1460702/000149315223015599/form8-k.htm" STYLE="-sec-extract: exhibit">May 5, 2023</A>, <A HREF="https://www.sec.gov/Archives/edgar/data/1460702/000149315223018231/form8-k.htm" STYLE="-sec-extract: exhibit">May 19, 2023</A>,
    <A HREF="https://www.sec.gov/Archives/edgar/data/1460702/000149315223022531/form8-k.htm" STYLE="-sec-extract: exhibit">June 26, 2023</A>, <A HREF="https://www.sec.gov/Archives/edgar/data/1460702/000149315223024516/form8-k.htm" STYLE="-sec-extract: exhibit">July 13, 2023</A>, <A HREF="https://www.sec.gov/Archives/edgar/data/1460702/000149315223025606/form8-k.htm" STYLE="-sec-extract: exhibit">July 26, 2023</A>, <A HREF="https://www.sec.gov/Archives/edgar/data/1460702/000149315223026170/form8-k.htm" STYLE="-sec-extract: exhibit">August 1, 2023</A> and <A HREF="https://www.sec.gov/Archives/edgar/data/1460702/000149315223026883/form8-k.htm" STYLE="-sec-extract: exhibit">August 4, 2023</A>; and</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    description of our common stock, which is registered under Section 12 of the Exchange Act, in our registration statement on <A HREF="https://www.sec.gov/Archives/edgar/data/1460702/000157104915005005/t1501385_8-a12b.htm" STYLE="-sec-extract: exhibit">Form 8-A</A>, filed with the SEC on June 15, 2015, as updated by <A HREF="https://www.sec.gov/Archives/edgar/data/1460702/000149315223024027/ex4-9.htm" STYLE="-sec-extract: exhibit">Exhibit 4.9</A> to Amendment No. 1 to our Annual Report on <A HREF="https://www.sec.gov/Archives/edgar/data/1460702/000149315223024027/form10-ka.htm" STYLE="-sec-extract: exhibit">Form 10-K</A> for the
    fiscal year ended December 31, 2022, filed on July 7, 2023.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
filings filed by us pursuant to the Exchange Act after the date of the initial filing of the registration statement of which this prospectus
is a part and prior to effectiveness of the registration statement shall be deemed to be incorporated by reference into this prospectus.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
also incorporate by reference any future filings (other than current reports furnished under Item 2.02 or Item 7.01 of Form 8-K and exhibits
filed on such form that are related to such items unless such Form 8-K expressly provides to the contrary) made with the SEC pursuant
to Sections 13(a), 13(c), 14 or 15(d) of the Exchange Act, including those made after the date of the initial filing of the registration
statement of which this prospectus is a part and prior to effectiveness of such registration statement, until we file a post-effective
amendment that indicates the termination of the offering of the shares of our common stock made by this prospectus and will become a
part of this prospectus from the date that such documents are filed with the SEC. Information in such future filings updates and supplements
the information provided in this prospectus. Any statements in any such future filings will automatically be deemed to modify and supersede
any information in any document we previously filed with the SEC that is incorporated or deemed to be incorporated herein by reference
to the extent that statements in the later filed document modify or replace such earlier statements.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">You
can request a copy of these filings, at no cost, by writing or telephoning us at the following address or telephone number:</FONT></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Qualigen
Therapeutics, Inc.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5857
Owens Avenue, Suite 300</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Carlsbad,
California 92008</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(760)
452-8111</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Attn:
Secretary</FONT></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">You
may also access the documents incorporated by reference in this prospectus through our website www.qlgntx.com. Except for the specific
incorporated documents listed above, no information available on or through our website shall be deemed to be incorporated in this prospectus
or the registration statement of which it forms a part.</FONT></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 19; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 18pt"><B>3,958,537
Shares</B></FONT></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"><IMG SRC="form424b3_001.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 14pt"><B>Common
Stock</B></FONT></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 12pt"><B>Prospectus</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 12pt"><B>September
7,</B></FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 12pt"><B> 2023</B></FONT></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 20; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>form424b3_001.jpg
<TEXT>
begin 644 form424b3_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" "* ,@# 2(  A$! Q$!_\0
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MQ@CCUY ]>/7M7^93J5RLID5QN3:^Y7P5?.3M8!0I.1G.&!!YSFOV$_X)E_\
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M^;8_#X&G4;C3]M)NI5E&SDJ-&G&I7JN*:<_9TI*":<Y1O'F_HPHK^4_X2_\
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M2PN-JT</@X2G&@J<*O+1A+#-3A7]O!PE*52%257VUXR2]GR_H_#?"/"5?A3
M2GEV Q<<;EM/$8K,:L(O$^UG2E*O4CB^:,\+]5J*K"$:4J4**PR4XSM4YO\
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M%O&?P:_X*2?ME:5\0_VH/C!X4_:(^)OA?X2_#?Q;XV\5_&GXV0ZYX>\&>&?
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M+_\ @LG^U3>>&O#OQ)^"_P"WE\5KW294;0S^TEJOQ0M="T"\O+<6US=V.O\
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L;D_=3]6;/YT9.U>3][^IH ?113 3O(SQCI^5 #Z*8I.1R?NG_P!"-% '_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>form424b3_002.jpg
<TEXT>
begin 644 form424b3_002.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" "U IX# 2(  A$! Q$!_\0
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M_P!A_P 61?LW>.?VM?$7[5_B?XF?#WPKXE\0_'KX*^ _BWXG^)?AC]H'XO\
M@6X\-_\ "M?!GPLT*#4O#G@KP7X.T3Q!XB^(^F^%M$\&^$?"]]I:>.-8&KQW
MFMZPI9#F<'RSH0A-RBHQG7PZC-.&+J.4:WMO86A'!UN?FJQ:LEO*/,1XMR2=
MY4\35JTHPG*I5I83&3]E*-;!8>-.5!898J4ZE7'48KV=":3<KOW*G+_27D#J
M1^8HW+Q\PYZ<CG/ Q]20/QK\:K[_ (*X>'],_;KT?]C%OA1H/B;2O%/Q+\7?
M!_P[\4_AM\?_  -\0-2B^(GA'P4?%4N@>-/AUIFCV@^'UU=:I%=^"[K3]?\
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M7[JYZ[1G\O?FEKR_Z_K;\EZ+9?0!112'D8]>/_K?CT_E0 ;E_O#\Q1N7&<C
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MTG_P8V?_ ,>H_M_0O^@UI/\ X,;/_P"/5\E_\.\OV#O^C+?V6_\ PP_PO_\
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MO)1A&"^M/[?T+_H-:3_X,;/_ ./4?V_H7_0:TG_P8V?_ ,>KY+_X=Y?L'?\
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M+H[D-&N/H@:]H?3^VM)P ,?\3*S_ /CWTKY,_P"'>7[!W_1EO[+?_AA_A?\
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M/_@QL_\ X]7R7_P[R_8._P"C+?V6_P#PP_PO_P#F;H_X=Y?L'?\ 1EO[+?\
MX8?X7_\ S-T7R_\ GS#_ ,)\'_\ -(<^;?\ 0-EO_A7C_P#YB/K3^W]"_P"@
MUI/_ (,;/_X]7SC^U#^SO\"OVO\ X9)\(OC1>3W_ (,B\9>#_'D<'AWQ@?#>
MHCQ#X%UF'7?#\QU*PG$YM(=0@C>ZM"#'=1CRY!@FN9_X=Y?L'?\ 1EO[+?\
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M@U-KY\(6VJ:FNH:A)!'+;7&FZ3+>&71M/T][33?L7=_\.\OV#O\ HRW]EO\
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MG@O_ )>?K117Y+_\/T/^"5'_ $=MH?\ X;'XX?\ SLJ/^'Z'_!*C_H[;0_\
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M/\F_\.>"_P#EY^M%%?DO_P /T/\ @E1_T=MH?_AL?CA_\[*C_A^A_P $J/\
MH[;0_P#PV/QP_P#G94?V'G?_ $)\T_\ #?B__E ?ZR\.?]#_ ";_ ,.>"_\
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MK117Y+_\/T/^"5'_ $=MH?\ X;'XX?\ SLJ/^'Z'_!*C_H[;0_\ PV/QP_\
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MHZ5ZBBBO9/RT**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M]KN)K']F/2+7P_#X>3Q)+';G1=>\):A?P6&IOK&K>$M>\$V_@AX[N]U;Q-K
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M_@LU;_Y;4?\ #G'_ ()A?]&6?!C_ ,%FK?\ RVK]+Z*/[5S7_H:9E_X7XO\
M^7A_J_D/_0CR;_PU9=_\Q'YH?\.<?^"87_1EGP8_\%FK?_+:C_ASC_P3"_Z,
ML^#'_@LU;_Y;5^E]%']JYK_T-,R_\+\7_P#+P_U?R'_H1Y-_X:LN_P#F(_-#
M_ASC_P $PO\ HRSX,?\ @LU;_P"6U'_#G'_@F%_T99\&/_!9JW_RVK]+Z*/[
M5S7_ *&F9?\ A?B__EX?ZOY#_P!"/)O_  U9=_\ ,1^:'_#G'_@F%_T99\&/
M_!9JW_RVH_X<X_\ !,+_ *,L^#'_ (+-6_\ EM7Z7T4?VKFO_0TS+_POQ?\
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M3?\ AJR[_P"8C\T/^'./_!,+_HRSX,?^"S5O_EM1_P .<?\ @F%_T99\&/\
MP6:M_P#+:OTOHH_M7-?^AIF7_A?B_P#Y>'^K^0_]"/)O_#5EW_S$?FA_PYQ_
MX)A?]&6?!C_P6:M_\MJ/^'./_!,+_HRSX,?^"S5O_EM7Z7T4?VKFO_0TS+_P
MOQ?_ ,O#_5_(?^A'DW_AJR[_ .8C\T/^'./_  3"_P"C+/@Q_P""S5O_ );4
M?\.<?^"87_1EGP8_\%FK?_+:OTOHH_M7-?\ H:9E_P"%^+_^7A_J_D/_ $(\
MF_\ #5EW_P Q'YH?\.<?^"87_1EGP8_\%FK?_+:C_ASC_P $PO\ HRSX,?\
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M8? A^/7[>!.?^'??AW.2?^3Q?A]U_P##=_IT]<TH^/?[>(.?^'??ATG&,_\
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M3$^'W_SNZ/\ A?O[>/\ TC\\._\ B8GP^_\ G=U]\X'H/R%&!Z#\A1];H_\
M0MP7_@6-_P#FT/[/QG_0ZS'_ , RS_YV'P-_POW]O'_I'YX=_P#$Q/A]_P#.
M[H_X7[^WC_TC\\._^)B?#[_YW=??.!Z#\A1@>@_(4?6Z/_0MP7_@6-_^;0_L
M_&?]#K,?_ ,L_P#G8? W_"_?V\?^D?GAW_Q,3X??_.[H_P"%^_MX_P#2/SP[
M_P")B?#[_P"=W7WS@>@_(48'H/R%'UNC_P!"W!?^!8W_ .;0_L_&?]#K,?\
MP#+/_G8? W_"_?V\?^D?GAW_ ,3$^'W_ ,[NC_A?O[>/_2/SP[_XF)\/O_G=
MU]\X'H/R%&!Z#\A1];H_]"W!?^!8W_YM#^S\9_T.LQ_\ RS_ .=A\#?\+]_;
MQ_Z1^>'?_$Q/A]_\[NC_ (7[^WC_ -(_/#O_ (F)\/O_ )W=??.!Z#\A1@>@
M_(4?6Z/_ $+<%_X%C?\ YM#^S\9_T.LQ_P# ,L_^=A\#?\+]_;Q_Z1^>'?\
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M_FT/[/QG_0ZS'_P#+/\ YV'P-_POW]O'_I'YX=_\3$^'W_SNZ/\ A?O[>/\
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MG2?#]C;Z;JEYJ\6CZG_6*>A^A[X_7M]:^7V_9J^"NG?M;-^U[Y>H6W[0>O?
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M'^+_ ,+%8=0WQ!\)*0>G(.KCOQT%)_PO;X)_]%A^%?\ X</PC_\ +>OPIO\
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M )T5'_$+Y_P3A_Z&?]I?_P +SX<?_.BH^J<*_P#0\S;_ ,,\/_G@']H<=?\
M1-9#_P")-6_^=9^\O_"]O@G_ -%A^%?_ (<3PC_\MZ/^%[?!/_HL/PK_ /#B
M>$?_ );U^#7_ !"^?\$X?^AG_:7_ /"\^''_ ,Z*C_B%\_X)P_\ 0S_M+_\
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M</\ T,_[2_\ X7GPX_\ G14?5.%?^AYFW_AGA_\ / /[0XZ_Z)K(?_$FK?\
MSK/WE_X7M\$_^BP_"O\ \.)X1_\ EO1_PO;X*$X'QA^%6?3_ (6'X1)_(:P*
M_!K_ (A?/^"</_0S_M+_ /A>?#C_ .=%3E_X-?\ _@G(C!E\4_M+<'A3X[^'
M) _\Q$/T.>:/JG"O_0\S7YY/"W_JP!9AQTW_ ,DWD"\_]9JS_!97<_;7XB_M
M3_L^?"[P%XJ^)?B_XQ?#^T\(^#-(N=<UZ]TWQ-H^OWL=E;@*L-AI&BW=]JFJ
MZC>7+P66FZ9IUK<WVHW]S;V=I!)/-&I^1_V1/^"LG[*G[9_Q(O\ X3?#+4?'
M?AGQ]%INI:SH7A_XE>%[#PY-XTTK1\2ZM=>%;O2];\0V%U<Z;9L-1NM$U&YT
MS7O[-6YU"#39[/3=4GL_AWQ'_P &Y?[(FE_#CQ?H'PC\?_&/PYXXU#1I8O">
MO>,=8\'^)?#^FZ];R1W>FSZ[H^D>!O#FH:AI,EU EOJ,-CJMC=BSGF>VF\Z.
M-3P/_!-/_@BY\:OV8?VFM$_:$^//CWX;W,'PUM/%$7@;PS\,]5\2:]<:_K?B
M/0=1\+'6?$&I:WX:\+QZ1HUCHFLZI/!I=M!J-_J.I2VGVF:RM;*5-1_.^(\7
MGV$XIR3!\-X99IPWB*=)YMC\3@J="K0J.O6AB8SD\PG+"JAAEAZU"4*-98JI
M*I3M&25O[ \(.%_ 3// 7Q8XC\6^+L9POXUY-6Q<?#SA7*<VQ-?"9G1IY7@*
MN33H8*/#U6CGKSC.JV.RS.(U\SRJID6#PU'&TIM5/:UOZ6(RS#+9'/0C!_+_
M #CIG.:DJ&%=H/7!P<D]\8(]L8'XGUJ:OHU>RO\ UO;\+'\YK;OOKWLVK_.U
M[=+VULFRBBBF,**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** &O]QO]UOY&OG_Q=\-/%'B+X@:)X_L_$EII\W@N;0D\):2UO:RV
MTEG/<7D/Q EU2]NM'N]3LKSQ#H.JS:1:0:+=16ROI.C7FIBX)-K:_0#8*L#T
M*G/TQ7R-\1/VW?V8?A-XTUOX>^/OB!JFB>,/#K6$6LZ;!\,?BOK\=JVHZ99Z
MS9*FK^'/ NK:)>>9I^H6LY-CJ-RD#RM;SF*ZBGACZ<+&O*HXX:C.M5Y)-QIT
MY5)>S?NSO%1:Y7>TD]7=675>+GF$RS&8:C3S6NZ&&I8O#XJG-8VI@?\ :\+4
M5;"2]K2G3G*5&M&.(IP<O9NK3A*I"HH\AC:5^S_X\LK5Q#XBT[2-2O=(\)>$
MM?U33O%7B_4;WQ'H;:5X@T/XF:]+<WNGP/I?BK7)-9LO%_AUH!=M9>*=(#7.
MKVXU'5;RYW=+^!_BR\\3:K>>+-1T2?PWK/B?2M5U7P_I.I:K;Z?J>GZ1'\4K
M4+)96>B:(Q:]L_%O@N.\L=7U/7Y;MO#D\=[K5W:66D6@X?\ X>0?L9'/_%U=
M<YZ_\69^./M_U33V%+_P\@_8S&,?%;7.!@?\69^./3C_ *II["N_V><-.^"Q
M>MM5@ZB:MMRNUURW:A_(G:-DK'QM+A?@:C&A".8<]+#U/:QHU<^<Z-1NFJ4X
MUZ7NPJTZ\;O%TVHPQDFY8J-:<ZU2OT]M\#_B#%I.K:=?:SH^L:MJ&E_#_3X_
M%\WB77!JRZ'X5L? 5OXB^'3V6H^&]9M(O#?BF^\-^)-<N]?,ES<7=WXEEM]7
M\-WIEO+N;<T?X->*=/\ %/@75[V_MM3M_#.J>']0.I:SXOU_5]<TS1]*\!^(
M/#%SX/LH(O#VE:'K5M-KVJ#Q&-;N+?0YK@W<T=YI*SZ1H\TGGG_#R#]C+_HJ
MNN?^&9^./<8/_--.XX^E'_#R#]C+_HJVN_\ AFOCEQ[#_BVO ]A_04G2S=I_
M[#B[^_\ \PE7[<'!_8T]UM<J:CVCJ;4^'N"J52E4CF,'*C/#5(.>=1GKA<4L
M;14U/G56V(2G*I657$RY*4OKD:E*E5I^F:S\,?&]UJOB6+2$T#3/!6IZRNN7
M?@F3QAKMUI_C#5+KQ7IVM:M=WLD?A2WN?A_:ZY91ZO)XBT?29O%FC^(=:U-9
M[JTMTCU*ZUS!D^!OQ#?2S GBZQAN[BQM(+SR-;\2Q&YMK;1]1L$\,SZRML-8
MGTOR+U/#<7B.8MKB:3OU\6RZV@M6Y#_AX_\ L8Y)_P"%JZWD@ G_ (4S\<<D
M#H/^2:=/:E_X>0_L9]?^%K:YVS_Q9GXX\XZ9_P"+:=NWIVIQI9M&UL!BM$E9
MX*<KI<N[:NW[JO)W;2BF[1CRNOD/!N)E6E7S3G]LZ[:AGD:,:<<16Q%:4*$:
M,::H4H/%5E2H4^6A3=2K4C26(Q&+Q&*]:L?A)K<'P?\ B'\/]N@Z9J7B[5O'
ME]I,-M?ZMJFC:-:>*-5N;[2K%]0O=-MM1DCTZVE2WD":<L-N%6WL(DM(H(HZ
MGC[X8_$?Q+=>/-/T;Q!IVF:+XGO_ !)JFF7X\3>)M-U73Y=:^#%M\.+'2DLM
M,TSRK"VTSQ+:_P#"5KJ5CK'FQ/-]IM-.CU> 74GF'_#R']C/_HJVN]<_\D:^
M.77_ ,-K^?KWI#_P4@_8R/7XJZX<=,_!GXXGOGJ?AH>_-0L/FJDW]0Q34N9M
M/!U':3C3A>-T[/EI]->9N5[W-\1E/"&(P5+ RS.%*E1PBP$98;.886K+"7S*
M4J,ZF'C!N$Y9KBVU"-*,$Z4:4:2H0<NLO/V?_$%G?:C<^%]4M=-M+Z^\4FXT
MI_$7BRVM=5\*:AXV^'7BG3O!5U-"+Z32-,NM/\/>,_#UU/I]M.N@0^,]2N=*
ML=1BOM6L;K2@^"?B,Z/X@35]2-Y=76DZ?IOA?3-,\:Z]96/A:"+XB^,/%$^B
MV>HZGH&LV=SI]MX:UGP[X3-SJ/A6\'B+1-$NO#6J:=I_AR[CMUX$_P#!1_\
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M<:-*%*#G/FAS3<8)RGRQYI.4N6/,XK[LV+Z?J?\ &D\M/[HKX4_X>0_L9_\
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M*/\ H9Y?_P"%E#_Y8?=?EI_=%'EI_=%?"G_#R']C/_HJ^O?^&;^.?_SM:/\
MAY#^QG_T5?7O_#-_'/\ ^=K1_9V8?] &,_\ ":M_\B']MY1_T,\O_P#"RA_\
ML/NORT_NBCRT_NBOA3_AY#^QG_T5?7O_  S?QS_^=K1_P\A_8S_Z*OKW_AF_
MCG_\[6C^SLP_Z ,9_P"$U;_Y$/[;RC_H9Y?_ .%E#_Y8?=?EI_=%&Q!T4"OA
M3_AY#^QG_P!%7U[_ ,,W\<__ )VM'_#R']C/_HJ^O?\ AF_CG_\ .UH_L[,/
M^@#&?^$U;_Y$/[:RC_H9Y?\ ^%F'_P#EA]V;%]/U/^- 1!T4#_/_ ->OA/\
MX>0_L9_]%7U[_P ,W\<__G:T?\/(?V,_^BKZ]_X9OXY__.UI?V;F#WP&,_\
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M*/\ H9Y?_P"%E#_Y8?=U%?"/_#R']C/_ **OKW_AF_CG_P#.UH_X>0_L9_\
M15]>_P##-_'/_P"=K1_9V8?] &,_\)JW_P B']MY1_T,\O\ _"RA_P#+#[NH
MKX1_X>0_L9_]%7U[_P ,W\<__G:T?\/(?V,_^BKZ]_X9OXY__.UH_L[,/^@#
M&?\ A-6_^1#^V\H_Z&>7_P#A90_^6'W=17PC_P /(?V,_P#HJ^O?^&;^.?\
M\[6C_AY#^QG_ -%7U[_PS?QS_P#G:T?V=F'_ $ 8S_PFK?\ R(?VWE'_ $,\
MO_\ "RA_\L/NZBOA'_AY#^QG_P!%7U[_ ,,W\<__ )VM'_#R']C/_HJ^O?\
MAF_CG_\ .UH_L[,/^@#&?^$U;_Y$/[;RC_H9Y?\ ^%E#_P"6'W=17PC_ ,/(
M?V,_^BKZ]_X9OXY__.UH_P"'D/[&?_15]>_\,W\<_P#YVM']G9A_T 8S_P )
MJW_R(?VWE'_0SR__ ,+*'_RP^[J*^$?^'D/[&?\ T5?7O_#-_'/_ .=K2_\
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M_"KPKJNFZQJ/AJ[\'P:78_;(M1\!FQ\76>L:7XAT[5;NUL8$U&U\H_X**?\
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M_P ]C1N7KD8]<BOS<_X*?_MN:Q^PA^SE%\4/"7A/2/&/CWQAX]TGX;>!]/\
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M/BIGK1_JQQ)_T),P^5'7_P!.K\P_UYX.Z<295?\ [")?_,Y_15D>H_.C<O\
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M_(U_7RT_KS3^91110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M!_\ R@H_X9H_9R_Z-]^"7_AI_ ?_ ,H*]SHH]OB/^@G$_P#A15_^6!]4PO\
MT#87_P )</\ _*3PS_AFC]G+_HWWX)?^&G\!_P#R@H_X9H_9R_Z-]^"7_AI_
M ?\ \H*]SHH]OB/^@G$_^%%7_P"6!]4PO_0-A?\ PEP__P I/#/^&:/V<O\
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M.T;0?BS<:3+=77B/0M8OM3\(7WBFR\&:O%>"V\$IINM_6O[3'[*'CSXH^*_
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C 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% '_]D!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
